Ajanta Pharma Limited, a speciality pharmaceutical formulation company, has received final approval from the United States Food and Drug Administration (USFDA) to market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg and 200 mg.
Topiramate is the generic version of Supernus Pharmaceuticals Inc's Trokendi XR™. As per the settlement with the innovator, Ajanta can launch Topiramate on February 1, 2026 or earlier under certain circumstances.
Ajanta has received 50 final ANDA approvals, out of which 41 are commercialized. Ajanta also holds 2 tentative approvals and 22 ANDAs are awaiting US FDA approvals.
Shares of Ajanta Pharma Limited was last trading in BSE at Rs. 1728.50 as compared to the previous close of Rs. 1724.90. The total number of shares traded during the day was 2518 in over 496 trades.
The stock hit an intraday high of Rs. 1730.80 and intraday low of 1704.30. The net turnover during the day was Rs. 4323766.00.